Guardant to highlight cancer screening studies at AACR

2020 06 01 18 51 2022 Cancer Lung 400

Guardant Health will highlight several studies of its portfolio of blood tests for cancer at the American Association for Cancer Research (AACR) annual meeting to be held April 8-13 in New Orleans.

Key presentations will include data from Guardant's multicancer screening assay, Guardant Shield.

”This data will demonstrate that our assay provides sensitive detection of early-stage cancers with accurate tissue of origin identification,” said Guardant co-CEO AmirAli Talasaz, in a news release.

The list of Guardant Health's presentations includes the following:

  • Development of a highly-sensitive targeted cell-free DNA epigenomic assay for early-stage multicancer screening (abstract 2141) 
  • CDK4/6 inhibitors (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with ESR1 mutations and fusions (abstract 5248)
  • Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence (abstract 3403/9)

The full abstracts can be found at the official AACR website.

Page 1 of 9
Next Page